Among the 13 New Chemical Entities/23 products added to Japan's National Health Insurance drug price list effective June 13, were world pharmaceutical giant Pfizer's Sutent (sunitinib) for imatinib-resistant gastrointestinal stromal tumor and renal cell cancer, US health care major Abbott Laboratories' Humira (adalimumab) for rheumatoid arthritis and Swiss drug major Novartis' Exjade (deferasirox) for hyperferremia.
The price of Sutent 12.5mg capsules for the treatment of imatinib-resistant GIST, and inoperative or metastatic RCC was set at 8,546.30 yen ($81.74) and a 5% premium for usefulness was granted. Sales of the drug are expected to reach 2.11 billion yen in the first year on the market and 14.09 billion yen at peak in the 10th.
Humira subcutaneous 40mg syringe 0.8ml, for use when existing therapy had failed, was set at 71,097 yen. Revenues from the antibody drug, which inhibitsTNF-alpha activity, are forecast to reach 2.33 billion yen in the first year and 38.89 billion yen at peak in the eighth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze